Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...

Novo Nordisk, which also makes Wegovy, fell victim to 'compounding' - a practice in the US that allows pharmacies to produce ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Bio-Techne surpasses profit expectations with significant growth in its research products, leading to the announcement of a ...

Novo Nordisk stock jumped early Wednesday despite cutting its 2025 outlook due to what Novo says is illegal compounding of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The celebrated actress has lost more than 100Ib after turning to controversial diabetes jab Ozempic - now better known for its impact on tackling obesity ...

We expected miracles—what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...